Enamine Ltd
Enamine Ltd is a Ukraine-headquartered contract research organization and chemical supplier providing 573,000+ building blocks, the trillion-scale REAL Space make-on-demand library, and integrated drug discovery services to pharmaceutical, biotechnology, and academic clients across more than 20 countries.
- Company typePrivate
- Founded1991
- HeadquartersMonmouth Junction, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Enamine Ltd does
Enamine Ltd is a privately held contract research organization and chemical supplier founded in 1991, headquartered in Kyiv, Ukraine, with research centers in Frankfurt (Germany) and Wroclaw (Poland), plus distribution offices in Riga (Latvia) and Monmouth Junction, New Jersey (USA). The company specializes in fine organic synthesis and provides chemical building blocks, screening compounds, and integrated drug discovery services to pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions across more than 20 countries. Its operations are anchored by over 650 skilled chemists and a biology team in which 40% of staff hold PhD degrees.
The company's core technology is the REAL (REadily AccessibLe) Space — a proprietary make-on-demand chemical library spanning trillions of synthetically feasible compounds built over 35 years — complemented by 573,000+ in-stock building blocks, 4.7+ million screening compounds, and 100+ pre-plated compound libraries. EnamineStore, a self-serve e-commerce platform, provides direct catalog access, while Computer-Aided Drug Design (CADD), the REAL Space Navigator (with BioSolveIT), and integrations with drug discovery software (Optibrium StarDrop, Cyclica Ligand Design, ChemAxon MadFast, ZINC/UCSF) embed Enamine's chemical data across the research workflow. The Integrated Drug Discovery (IDD) service platform extends these assets into end-to-end drug discovery programs spanning hit identification, hit-to-lead chemistry, ADME/PK, biology, and preclinical candidate support.
Enamine generates revenue through two principal streams: catalog product sales (building blocks, screening compounds, and pre-plated libraries priced per unit via EnamineStore) and fee-for-service drug discovery collaborations (custom synthesis, FTE chemistry support, IDD programs) with pharmaceutical and biotechnology clients. Long-standing multi-year partnerships with major pharmaceutical companies (Sanofi, Lundbeck, Pfizer, Addex Therapeutics, Actelion Pharmaceuticals) and a growing roster of biotechnology and AI-driven partners (Recursion, Atomwise, Peapod Bio, Nuclide Therapeutics, Variational AI, SyntheticGestalt) indicate a diversified customer base spanning enterprise, mid-market, and academic segments across multiple therapeutic areas including CNS, oncology, infectious disease, and radiopharmaceuticals.
Enamine Ltd firmographics
Firmographics- Name
- Enamine Ltd
- Legal name
- ENAMINE Ltd.
- Website
- https://enamine.net
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Enamine Ltd is a Ukraine-headquartered contract research organization and chemical supplier providing 573,000+ building blocks, the trillion-scale REAL Space make-on-demand library, and integrated drug discovery services to pharmaceutical, biotechnology, and academic clients across more than 20 countries.
- Ownership category
- akta.pro rank
Enamine Ltd industry classification
Industry- Product category
- Drug Discovery Contract Research and Chemical Building-Block Supply
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Enamine Ltd is headquartered
LocationHeadquarters
- HQ city
- Monmouth Junction
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Enamine Ltd business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Compound Sales: Sale of building blocks, screening compounds, and compound libraries through EnamineStore e-commerce platform and catalog sales. Products include over 573,000 building blocks in stock, diverse compound libraries, and custom synthesis options.
- Integrated Drug Discovery Services: Fee-for-service drug discovery research including synthetic chemistry, medicinal chemistry, ADME/PK, hit-to-lead chemistry, biology services, and FTE chemistry support for pharmaceutical and biotech clients.
- Custom Synthesis: Custom synthesis services for complex compounds with world-class quality, including late-stage functionalization, flow chemistry, and specialized medicinal chemistry support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Building blocks and screening compounds sold individually with pricing based on quantity and synthesis complexity |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels7 records
Enamine Ltd product offering
Product offeringCore offering
Enamine manufactures and supplies chemical building blocks, screening compounds, fragment libraries, and make-on-demand libraries (REAL Space and xREAL Space) used in early-stage drug discovery. The company delivers contract research services spanning custom synthesis, library synthesis, integrated drug discovery (IDD), computer-aided drug design (CADD), and biology/DMPK assays, serving pharmaceutical, biotechnology, and academic customers.
Product overview
Enamine Ltd is a contract research organization (CRO) specializing in fine organic synthesis and drug discovery services, operating as a platform-plus-modules architecture. The core platform consists of EnamineStore, an e-commerce portal for accessing the company's extensive chemical collections. The main product modules include Building Blocks (573,000+ compounds in stock across multiple specialty categories), REAL Compounds/REAL Space (the world's largest make-on-demand library spanning trillions of compounds), Compound Libraries (100+ pre-plated libraries including AI-enabled, diversity, targeted, and fragment libraries), and Screening Collections. Service modules encompass Integrated Drug Discovery (IDD) for end-to-end drug discovery, Library Synthesis, Custom Synthesis, CADD, Biology Services, FTE Chemistry Support, Hamilton Verso automated storage, UFrag Library, and Hit Follow-up Support. The company maintains research centers in Kyiv (headquarters), Frankfurt, and Wroclaw, with distribution through Enamine LV SIA (EU) and Enamine US Inc. (North America).
Differentiator
Problem solved
Functional benefit
Brands
- REAL (REadily AccessibLe compounds): Enamine's flagship make-on-demand compound collection comprising trillions of synthetically accessible chemical compounds for drug discovery.
- xREAL Space
- MADE Building Blocks
- Integrated Drug Discovery (IDD)
Products and services
- Building Blocks Catalog On-demand supply of more than 573,000 in-stock building blocks across multiple pack sizes (typically 100 mg–2.5 g) for medicinal chemistry and drug discovery customers worldwide.
- REAL Space Make-on-Demand Compound Library Make-on-demand chemical library spanning trillions of accessible structures, designed and selected using EnamineStore, the REAL Space Navigator, and BioSolveIT infiniSee for hit identification and library design.
- xREAL Space Frozen Library xREAL Space offers the benefits of REAL Space in a defined, frozen format suitable for routine screening, providing on-demand access to large, design-focused chemistry sets.
- Screening Collections and Pre-Plated Libraries More than 100 pre-plated screening collections for high-throughput biology and lead discovery, available alongside custom library design services.
- uFrag Fragment Library A fragment-based discovery program offering a low-molecular-weight collection tailored for fragment-based ligand discovery and optimization.
- Custom Synthesis Services Custom synthesis of non-listed organic molecules and building blocks under defined timelines, supporting medicinal chemistry and analoging programs.
- Library Synthesis Services Design and synthesis of focused and targeted compound libraries based on customer-specified scaffolds, hypotheses, or AI-generated designs.
- Integrated Drug Discovery (IDD) End-to-end drug discovery service combining medicinal chemistry design, custom synthesis, in-vitro and in-vivo biology, ADME, and PK studies to advance candidates from hit to development candidate.
- Computer-Aided Drug Design (CADD) Computational chemistry services covering virtual screening, structure- and ligand-based design, pharmacophore modeling, and AI-driven library design for early-stage discovery projects.
- Biology and DMPK Services In vitro and in vivo biology, pharmacology, and DMPK assay services supporting SAR studies, lead optimization, and preclinical candidate selection within integrated or standalone engagements.
- Hamilton Verso Automated Compound Management Automated compound storage and management service built around Hamilton Verso, supporting acquisition, quality control, repacking, and plating of customer compound collections.
- Hit Follow-Up and Lead Optimization Support Synthetic chemistry support for analoging, SAR generation, and lead optimization, combined with biology feedback to progress screening hits into development-quality leads.
- EnamineStore E-Commerce Platform Enamine's online e-commerce platform that lets customers browse, price, and order catalog building blocks, screening collections, and pre-plated libraries directly, with account-management tools for institutional customers.
Quantifiable outcome
- Delivered development milestones ahead of schedule with efficient resource use for Nuclide Therapeutics radiotheranostics pipeline
- +3 more outcomes
Companies that use Enamine Ltd
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles3 records
Enamine Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability5 records
Feature6 records
Enamine Ltd partnerships and signals
Strategic signalPartnerships
29 partnerships are on record, tiered core and minor.
- Pohang Accelerator Laboratory (PAL)coreCollaborative framework for crystallographic fragment screening, combining PAL's public crystallography infrastructure with Enamine's compound libraries and hit-to-lead chemistry services.
- SyntheticGestaltcoreStrategic partnership to advance AI models for drug discovery, combining SyntheticGestalt's molecule-specialized foundation AI model SG4D10B with Enamine's chemical synthesis expertise and compound libraries.
- Chemspace and Paul Scherrer InstitutecoreJoint service for fragment-based lead discovery combining Chemspace's ML-guided hit identification, Enamine's REAL Space and synthetic chemistry, and PSI's crystallographic screening at the Swiss Light Source.
- Agora Open Science Trust and Variational AIcoreOpen-science collaboration to discover PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA) using AI-driven design and synthetic chemistry with open science principles.
- ChemspacecoreIntegration of Enamine's xREAL Space into Chemspace platform, enabling researchers worldwide to search and purchase trillions of make-on-demand chemical compounds through a single online source.
- EMUNO TherapeuticscoreComprehensive collaboration advancing EMUNO's small molecule programs in immuno-oncology aimed at achieving clinical impact for challenging malignancies, supported by EIC Transition Grant.
- ABX-CROcoreCollaboration supporting ABX-CRO's translational medicine approach for imaging agents and radiopharmaceuticals through integrated competencies in biology, chemistry, and computational sciences.
- IHI Project LIGAND-AIcoreMultinational initiative with 18 partners across nine countries to advance AI-driven drug discovery with €60M+ budget, generating large datasets of protein-ligand interactions and fostering open science.
- Peapod Bio Inc.coreStrategic collaboration combining Peapod Bio's high-throughput screening technologies with Enamine's extensive small molecule libraries to accelerate hit discovery and drug development.
- Institute of Cancer Research (ICR), LondoncoreResearch collaboration to broaden tools available for Fragment-based Drug Discovery (FBDD) using fluorinated compound libraries.
- CACHE (Critical Assessment of Computational Hit-finding Experiments)coreEnamine joined the CACHE Governing Board, serving as primary supplier of compounds for challenges since inception.
- Orogen Therapeutics and ChemspacecoreCollaboration to design, build, and test novel DNA-encoded libraries (DEL) combining Chemspace's chemi-informatics, Enamine's REAL design principles, and Orogen's DEL expertise.
- Qanatpharma, Zuse Institute Berlin, and Proteros biostructurescoreGenerative-AI driven lead discovery collaboration targeting cerebral perfusion deficits associated with subarachnoid hemorrhage.
- PfizerminorSelected Pfizer reference compounds made available through Enamine's marketplace and integration capabilities for researchers to explore and purchase.
- Pohang Accelerator Laboratory (PAL)coreMOU to advance collaborative drug discovery in fragment-based drug discovery and hit optimization, combining advanced screening technologies with fast-track chemical development.
- Korean Chemical Society (KCS)minorMOU for cooperation across academic and business domains to strengthen research and scientific exchange in chemical science.
- RecursioncoreRelease of 10 AI-enabled targeted compound libraries comprising over 15,000 newly synthesized compounds designed for 100 key drug targets, combining Recursion's AI/ML platform with Enamine's REAL Space.
- Nuclide TherapeuticscoreCollaboration since 2025 to advance Nuclide's radiotheranostics pipeline for therapy-resistant cancers toward IND-enabling studies and first-in-human clinical trials using Enamine's synthetic chemistry and REAL Space platform.
- BioSolveITcoreExclusive partnership establishing world's most comprehensive chemical space exploration platform, superseding the successful REAL concept with access to billions of compounds.
- Addex TherapeuticscoreExtended multi-year CNS drug discovery collaboration using allosteric modulation-based approaches with integrated medicinal chemistry and ADME/PK capabilities.
- AIDD (Advanced Machine Learning for Innovative Drug Discovery)coreEU-funded Horizon 2020 project with €3.93M budget to develop next-generation AI and ML models for drug discovery, training 16 PhD students across 15 institutions.
- CyclicacoreIntegration of Enamine's REAL Space with Cyclica's AI-driven Ligand Design platform for polypharmacological compound identification from over 11 billion compounds.
- AtomwisecoreCollaboration for world's first and largest ten billion compound virtual screen for pediatric oncology drug discovery using AI and novel chemistry.
- LundbeckcoreExtended multi-year drug discovery collaboration providing screening libraries, hit finding activities, and FTE chemistry support for multiple CNS research programs.
- OptibriumcoreIntegration of REAL Space Search tool into StarDrop software enabling efficient search of over 11 billion readily accessible compounds from within the drug design platform.
- European Molecular Biology Laboratory (EMBL)coreCollaboration for discovery and development of novel small molecules against EMBL's proprietary anti-cancer targets using library synthesis and medicinal chemistry.
- Actelion PharmaceuticalscoreExpanded collaboration in early drug discovery covering cardiovascular, CNS, immunology, infectious diseases, and oncology therapeutic areas.
- UkrOrgSynthesis Ltd (UORSY)coreCollaboration making combined companies the largest global manufacturer and seller of building blocks with 60,000 products in stock and ~8 million tangible building blocks.
- ChemBridge Corporation and FCH GroupcoreLaunch of Chem-Space global e-procurement marketplace encompassing over 15 million unique molecular building blocks as world's largest chemicals library.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Enamine Ltd competitors and assessment
Company assessmentDirect peers
- Life Chemicals: Direct competitor in screening libraries and building blocks for early drug discovery, offering similar catalog and custom synthesis services to pharma/biotech.
- ChemBridge Corporation: Direct competitor in building blocks and screening compound catalogs. Co-founded the Chem-Space marketplace with Enamine in 2016 and has overlapping product lines in molecular building blocks and screening libraries.
- MolPort: Chemical marketplace aggregating building blocks from multiple suppliers, directly competing with EnamineStore for screening compound purchases by pharma and biotech researchers.
- Combi-Blocks: Direct competitor in chemical building blocks for drug discovery, offering a deep catalog of screening compounds and custom synthesis services to pharma/biotech customers.
- PharmaBlock Sciences: Building block and CDMO competitor with comparable catalog-plus-services model. Supplies pharma with intermediates, building blocks, and custom synthesis at scale.
- ChemSpace: Chemical marketplace partner/distributor hosting xREAL Space integration. Operates adjacent marketplace for the same building block and screening compound customer base.
- Asinex: Building block and screening library supplier with overlapping catalog offerings for medicinal chemistry customers, including pre-plated libraries and custom synthesis.
Broad incumbents
- WuXi AppTec: Larger CRO/CDMO incumbent offering end-to-end drug discovery and development services. Competes with Enamine's IDD platform but on a much broader scale across modalities.
Emerging players
- BioSolveIT: Drug discovery software partner co-developing REAL Space Navigator. Sells cheminformatics tools that access Enamine's catalog — adjacent technology partner rather than pure competitor.
Regional players
- Vitas-M Chemical: Building block supplier with similar catalog and custom synthesis focus; primarily serves European pharma/biotech with comparable small-molecule libraries.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Enamine Ltd social profiles
Digital presenceEnamine Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enamine Ltd leadership team
Management profileNumber of profiles
Profiles7 records
Enamine Ltd subsidiaries and ownership
Company hierarchySubsidiaries3 records
Enamine Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enamine Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enamine Ltd
What does Enamine Ltd do?
Enamine manufactures and supplies chemical building blocks, screening compounds, fragment libraries, and make-on-demand libraries (REAL Space and xREAL Space) used in early-stage drug discovery. The company delivers contract research services spanning custom synthesis, library synthesis, integrated drug discovery (IDD), computer-aided drug design (CADD), and biology/DMPK assays, serving pharmaceutical, biotechnology, and academic customers.
Is Enamine Ltd a public or private company?
Enamine Ltd is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Enamine Ltd founded?
Enamine Ltd was founded in 1991. It employs 1,001 to 5,000 people.
Where is Enamine Ltd based?
Enamine Ltd is headquartered in Monmouth Junction, United States, in the North America region.
How does Enamine Ltd make money?
Three revenue lines are on record. Compound Sales are the primary driver. The others are integrated Drug Discovery Services and custom Synthesis.
Who are Enamine Ltd's main competitors?
Direct peers on record are Life Chemicals, ChemBridge Corporation, MolPort, Combi-Blocks, PharmaBlock Sciences, ChemSpace and Asinex. WuXi AppTec is listed as a broad incumbent. BioSolveIT is listed as an emerging player. Vitas-M Chemical is listed as a regional player.
Does Enamine Ltd have an API?
No public API is recorded for Enamine Ltd.
What industry is Enamine Ltd in?
Enamine Ltd's product category is Drug Discovery Contract Research and Chemical Building-Block Supply. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 32541 and its SIC code is 2833.